Nitrosamines have become a significant concern in the pharmaceutical industry due to their potential carcinogenic risks. Regulatory agencies such as the FDA, EMA, and ICH have imposed strict ...
In 2018, a nitrosamine impurity (N-nitrosodimethylamine or “NDMA”) was detected in several pharmaceutical drugs containing the active ingredient valsartan, which resulted in a voluntary product recall ...
Nitrosamine impurities became a topic of focus when health regulators recalled valsartan, an antihypertensive drug, due to the presence of N-nitrosodimethylamine (NDMA), a probable carcinogenic agent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results